Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | FLT4 | P35916 | 2/20 | 0.33 |
| ▸ | FLT3 | P36888 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353300 | 0.92 | CASP3 (0.34) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14353015 | 0.91 | MAP2K1 (0.34) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14353027 | 0.90 | PYGL (0.32) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL14352930 | 0.89 | CASP3 (0.32) | CASP3BACE1 | |
| SCHEMBL4497747 | 0.86 | F2 (0.39) | MEN1KMT2ACASP3BACE1AURKB | |
| SCHEMBL25754137 | 0.85 | MEN1 (0.38) | MEN1KMT2ARETCASP3BACE1 | |
| SCHEMBL10293630 | 0.84 | MAP2K1 (0.40) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL10325117 | 0.84 | MAP2K1 (0.40) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL15409472 | 0.83 | MAP2K1 (0.33) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL15409478 | 0.83 | MAP2K1 (0.33) | MEN1KMT2ANPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194442-A1 | ANTICANCER THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-10 | — | — | US | claimed |
| US-20130122005-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| US-20130004481-A1 | ANTICANCER THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-03 | — | — | US | claimed |
| US-8937095-B2 | Anticancer compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140194442-A1 | ANTICANCER THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140018405-A1 | Anticancer Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-2663303-A1 | ANTICANCER THERAPY WITH DUAL AURORA KINASE / MEK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130122005-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130004481-A1 | ANTICANCER THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-03 | — | — | US | disclosed |
| WO-2012095505-A1 | ANTICANCER THERAPY WITH DUAL AURORA KINASE / MEK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194442-A1 | ANTICANCER THERAPY | AURKA, AURKC, AURKB | MEN1 1688/4885KMT2A 879/4885NPC1 1156/4885 |
| US-20130004481-A1 | ANTICANCER THERAPY | AURKA, AURKC, AURKB | MEN1 1688/4885KMT2A 879/4885NPC1 1156/4885 |
| US-20140018405-A1 | Anticancer Compounds | AURKA, AURKC, AURKB | MEN1 842/4885KMT2A 591/4885NPC1 936/4885 |
| US-20130122005-A1 | ANTICANCER COMBINATION THERAPY | AURKA, IGF1R, AURKC | MEN1 430/4885KMT2A 892/4885NPC1 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.